See editorial on page 34; and related article on page 139. I nflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract with a significant burden on patients' quality of life. Diarrhea is a common symptom in ulcerative colitis (UC) and Crohn's disease (CD). In addition, patients with UC often present with rectal bleeding (RB) and report abdominal pain (AP) in CD. 1, 2 Consequently, these important symptoms are regularly used as endpoints in clinical trials as a part of disease activity indices and to monitor disease activity in clinical practice. 3 Current therapy aims to resolve relevant symptoms and underlying mucosal inflammation. 4 Patient-reported outcomes (PROs) have an increasingly important role in capturing symptomatic burden and have become required by regulatory agencies in assessing response to treatment and evaluation of claims for future product labeling. [4] [5] [6] Several studies have identified the resolution of RB and the normalization of bowel habit as primary PRO targets for UC therapy. 4, 5 In CD, Khanna et al 7 recommended the resolution of AP and the normalization of bowel habit as the primary PROs for the evaluation of CD treatment efficacy in clinical trials.
Vedolizumab is a gut-selective humanized IgG1 monoclonal antibody that binds to a 4 b 7 integrin expressed on the surface of lymphocytes, thereby blocking the binding of a 4 b 7 to its ligand MAdCAM-1 (mucosal addressin cell adhesion molecule-1) expressed on the endothelial surface of venules in lymphoid tissue in the gastrointestinal tract. The binding of vedolizumab to a 4 b 7 prevents the a 4 b 7 -expressing T lymphocytes from entering gut tissue, thus reducing inflammation. 8, 9 In the GEMINI trials, vedolizumab's efficacy as induction and maintenance therapy was demonstrated in patients with moderately to severely active UC or CD who were naive to, or had prior exposure to, tumor necrosis factor-a (TNF) antagonists. [10] [11] [12] Clinical benefits of vedolizumab in patients with UC were evident at Week 6, with greater differences in efficacy between vedolizumab and placebo observed in patients who were TNF antagonist-naive compared with those who failed TNF antagonist treatment. 10, 13 Subgroup analyses of patients with CD indicated that significantly higher remission and response rates were achieved in TNF antagonist-naive patients treated with vedolizumab than those assigned to placebo at Weeks 6 and 10. In patients who failed TNF antagonist treatment, a significant effect of vedolizumab induction on clinical remission was observed at Week 10. 12 These data add to the growing evidence that second-generation biologics, such as vedolizumab and ustekinumab, have higher efficacy in TNF antagonist-naive patients in both clinical trials and real-world settings. 12, 14, 15 Recent trends in clinical practice are moving toward incorporating disease-modifying therapy earlier in the treatment of IBD to prevent disease progression and cumulative bowel damage; hence, the importance of evaluating the treatment effects of vedolizumab in biologic-naive patients. 16, 17 It has been debated whether agents affecting lymphocyte trafficking may have a relatively slower onset of action, especially in CD. However, there are no published studies comparing the rapidity of onset of various classes of IBD drugs. The objective of this study was to investigate the time course of clinical response with vedolizumab, particularly when used as a first-line biologic. Therefore, we performed exploratory analyses of the GEMINI trial data to assess rapidity of onset and identify predictors of patient-reported symptom improvements with vedolizumab in patients with UC or CD.
Methods

Study Design
The results are based on post hoc exploratory analyses of the phase 3, randomized, placebo-controlled trials GEMINI 1, GEMINI 2, and GEMINI 3. The design of the trials is reported in detail elsewhere 10, 11, 18 and summarized in Supplementary Figure 1 . To summarize, eligible patients were aged 18-80 years and had UC for 6 months with a Mayo Clinic Score (MCS) of 6-12 points and endoscopic subscore of 2 in GEMINI 1, or had CD for 3 months and a Crohn's disease activity index (CDAI) score of 220-450 in GEMINI 2 and 3. Patients were randomized to induction treatment for 6 weeks (GEMINI 1 and 2) or 10 weeks (GEMINI 3) and received 300-mg intravenous vedolizumab or placebo at Weeks 0 and 2 (GEMINI 1 and 2) or Weeks 0, 2, and 6 (GEMINI 3). These patients are referred to as the induction intent-to-treat population and are the focus of these analyses.
Disease activity at entry into GEMINI and efficacy assessments throughout the studies were measured by MCS for UC and CDAI for CD. Patient-reported components of MCS were RB and stool frequency (SF), and those of CDAI were AP and loose SF (LSF).
Patient-Reported Outcomes
Mean percentage changes from baseline in patientreported subscores were calculated for the overall population, TNF antagonist-naive, and TNF antagonistexposed patients at 2, 4, and 6 weeks. Percentages of patients with UC who reached RB subscore ¼ 0
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Findings
Vedolizumab improved patient-reported symptoms of UC and CD as early as Week 2 of treatment, with continuing improvement through Week 6-especially for TNF-naive patients.
Implications for patient care
These findings have implications for optimal positioning of vedolizumab in treatment algorithms. The rapid improvement of UC and CD symptoms in TNFnaive patients supports vedolizumab's use as a firstline biologic.
(elimination of bleeding) and SF subscore 1 (no more than 1 to 2 stools above normal) and of patients with CD who achieved average daily composite score of AP 1 and LSF 3 (revised ) were determined at each timepoint (Weeks 2, 4, and 6).
Statistical Analyses
The difference in adjusted percentage score change from baseline between vedolizumab and placebo was determined using an analysis of covariance model with treatment as a factor and baseline score as a covariate, and study as an additional factor for GEMINI 2 and 3. The 95% confidence intervals were calculated, and upper limit of 95% confidence interval <0 was considered statistically significant at a nominal significance level of 0.05, unless otherwise indicated. For the pooled GEMINI 2 and 3 analyses, the Cochran-Mantel-Haenszel method with "study" as a stratum was used to adjust for treatment differences in the proportion of patients with CD who achieved average daily composite score of AP 1 and LSF 3.
Univariate logistic regression analyses were performed to identify predictors of outcomes at Week 2 (composite subscores of RB ¼ 0 and SF 1 for UC, and AP 1 and LSF 3 for CD). P values .05 were considered statistically significant. A multivariate analysis was performed by fitting baseline variables from the univariate analyses with a P < .05 using stepwise backward regression. For CD, "study" as a factor was included at each step of model building to adjust for potential study differences between GEMINI 2 and 3.
Results
Patient Baseline Characteristics
A total of 374 patients with UC (GEMINI 1) and 784 patients with CD (GEMINI 2 and 3) were randomized for induction to receive vedolizumab or placebo, and these constituted the induction intent-to-treat population. TNF antagonist-naive patients constituted 55% (n ¼ 206) and 36.5% (n ¼ 286) of the UC and CD populations, respectively. No statistical comparisons were made between subpopulations. However, a descriptive summary of baseline characteristics showed a few notable differences within the UC population (Supplementary Table 1) . Disease activity at baseline was similar across treatment groups with median MCS of 8.0 for vedolizumab versus 9.0 for placebo in the overall UC population, 8.0 for both vedolizumab and placebo in the TNF antagonist-naive, and 9.0 for both vedolizumab and placebo in the TNF antagonist-exposed patients. Median disease duration was shorter in TNF antagonist-naive (placebo, 3.4 years; vedolizumab, 3.9 years) than TNF antagonist-exposed patients (placebo, 5.3 years; vedolizumab, 5.0 years) 
Symptom Improvement With Vedolizumab in Patients With Ulcerative Colitis
Numerically greater percentage decreases from baseline in RB subscore were observed with vedolizumab treatment than with placebo, reaching statistical significance at Weeks 4 and 6 in both overall and TNF antagonist-naive. No significant differences between vedolizumab and placebo were observed in TNF antagonist-exposed patients ( Figure 1A-C) .
In the overall population, statistically significant percentage decreases in SF subscore from baseline were observed with vedolizumab than with placebo at Weeks 4 and 6 and at all timepoints in TNF antagonist-naive patients ( Figure 1D and E). No significant differences between vedolizumab and placebo were observed in the TNF antagonist-exposed population ( Figure 1F ).
Significantly larger percentages of patients achieved a composite score of RB ¼ 0 and SF 1 with vedolizumab than placebo at all timepoints in the overall and TNF antagonist-naive populations (Figure 2A and B). No significant differences between vedolizumab and placebo were observed in the TNF antagonist-exposed population ( Figure 2C ).
Symptom Improvement With Vedolizumab in Patients With Crohn's Disease
Percentage score decrease from baseline was evaluated in the pooled GEMINI 2 and 3 populations. GEMINI 2 was composed of 50% TNF antagonist-naive patients, whereas GEMINI 3 consisted of predominantly TNF antagonist-failure population (failure, 76%; naive, 24%) (Supplementary Table 3 ). Significantly greater percentage decreases in AP subscore from baseline were observed with vedolizumab than placebo as of Week 4 in the overall GEMINI 2 and 3 combined ( Figure 3A ). In TNF antagonist-naive patients, there was a significantly greater decrease in the AP subscore with vedolizumab than placebo as of Week 4 ( Figure 3B ). No significant differences were observed in the TNF antagonist-exposed population ( Figure 3C ).
Greater percentage decreases in LSF were observed with vedolizumab than placebo, reaching statistical significance as of Week 2 in all populations ( Figure 3D Overall, differences in percentage subscore reduction between vedolizumab and placebo were greater in the TNF antagonist-naive patients than in the overall and TNF antagonist-exposed populations. Notably, differences in the percentage decrease from baseline in the AP subscore among the TNF antagonist-naive patients at Week 2 (-7.2), Week 4 (-18.7), and Week 6 (-17.7) were about 2 times as high as in the overall population (-3.8, -6.4, and -6.9, respectively) ( Figure 3A and B).
Significantly larger percentages of patients achieved an average daily composite score of AP 1 and LSF 3 with vedolizumab than placebo at Weeks 2 and 4 in the TNF antagonist-naive group and only at Week 4 in the overall population, but not in the TNF antagonistexposed group ( Figure 5 ).
Predictors of Symptomatic Improvement in Ulcerative Colitis and Crohn's Disease at Week 2
Univariate analyses of UC outcome predictors identified disease severity, baseline partial and complete MCS, and baseline SF subscore as significant variables (P .05) for achieving the composite score of RB subscore ¼ 0 and SF subscore 1 (Supplementary Table 4 ). In multivariate analyses, baseline complete MCS remained significant and lower baseline MCS was associated with achieving RB subscore ¼ 0 and SF subscore 1 (Supplementary Table 5 ).
In CD, univariate analyses of outcome predictors identified male sex, CD duration of <2 or <5 years, no prior bowel surgery, no previous exposure or failure to TNF antagonists, corticosteroid use, lower baseline CDAI, Harvey-Bradshaw index, and LSF scores as significant predictors for achieving the composite score of AP 1 and LSF 3 (Supplementary Table 6 ). A multivariate analysis confirmed a CD duration of <5 years, corticosteroid use, and lower baseline CDAI score as significant predictors of Week 2 outcome (Supplementary Table 5 ).
Discussion
These exploratory, post hoc analyses indicated that vedolizumab was effective at reducing patient-reported symptoms as of Week 2 in patients with UC or CD, with continued improvement throughout the first 6 weeks of treatment. More specifically, 40.8% of TNF antagonist-naive patients with UC achieved both elimination of RB (RB subscore ¼ 0) and reduction in SF (SF subscore 1) at Week 6 with vedolizumab compared with 13.2% with placebo. In CD, greater percentage decreases from baseline in combined AP and LSF score were observed with vedolizumab (32.0%) than placebo (16.0%) in the TNF antagonist-naive patients after 6 weeks. The efficacy of vedolizumab for inducing response and remission was demonstrated in the GEMINI trials, whereby clinical benefits were more likely to be achieved at Week 6 in patients treated with vedolizumab than those assigned to placebo. The rapid onset of vedolizumab's action reported here suggests that symptomatic improvements may precede observed benefits by objective measures of disease activity.
To assist with clinical interpretation of these data, we explored changes in complete MCS and CDAI that corresponded with the percentage change from baseline in the individual symptomatic improvements. At Week 6, the change in RB subscore (overall, w50%; TNF antagonist-naive, w60%) and SF subscore (overall, 25%; TNF antagonist-naive, w37%) were associated with an approximate reduction of 2.7-2.9 and 3.3-3.5 points in complete MCS in the overall and TNF antagonist-naive GEMINI 1 populations, respectively. In GEMINI 2 and 3, a change in AP subscore of 25.4% and LSF subscore of 25.2% corresponded to an approximate 80-point reduction in CDAI score in the overall population. In TNF antagonist-naive populations, changes of 32.8% and 30.9% in AP and LSF subscores, respectively, corresponded to an approximate 98.6-point reduction in CDAI score.
Although there is no published evidence to establish a correlation between early patient-reported symptomatic improvement and long-term treatment benefits, several studies have demonstrated that PROs are responsive to treatment effects. Specifically, in a post hoc analysis of 2 independent studies in UC, the combination score of RB ¼ 0 and SF 1 (defined as PRO2) was able to differentiate a treatment effect between active drug and placebo and was significantly associated, alone or in combination with endoscopy, with clinical response. 5 In addition, symptom scores generally correlated well with endoscopic scores in UC, but some patients still exhibited persistent symptoms even after endoscopic healing. 16 Similarly in CD, 2-or 3-item PROs consisting of SF and RB, or SF, RB, and general well-being, respectively, were responsive to change in disease activity and indicated similar treatment effects as CDAI-based outcomes. highlighting the need to further assess the relationship between symptoms and disease activity, particularly in CD. In a real-world setting, symptom-based clinical response to vedolizumab at Week 4 was found to be an independent predictor of long-term mucosal healing (up to 12 months) for UC and CD. 21 In general, reductions from baseline in symptom scores with vedolizumab versus placebo were observed in the overall intent-to-treat UC or CD population, but were greater in TNF antagonist-naive patients. These observations are consistent with published clinical trial and real-world data supporting the efficacy of vedolizumab in TNF antagonist-naive patients at Week 6 and beyond. In a post hoc analysis of GEMINI 1 and GEMINI 2 data, TNF antagonist-naive vedolizumab-treated patients with UC and CD had greater differences versus placebo at Week 6 than patients who had previous TNF antagonist failure, specifically in clinical response and remission in UC and CD and mucosal healing in UC. 13, 18 A German real-world study observed that vedolizumab was significantly more effective at inducing clinical remission (partial MCS 1 with RB ¼ 0) at Week 54 in TNF-naive than in TNFexposed patients with UC (55% vs 18%; P ¼ .02). 22 A network meta-analysis of 5 studies provides further evidence for the benefits of vedolizumab maintenance therapy over other biologics among TNF antagonist-naive patients with UC, 23 25 Overall, our results in addition to published evidence indicate that vedolizumab could be considered as a viable first-line biologic option for patients with UC and CD who are TNF antagonist-treatment naive.
Previous studies have evaluated the predictors of response to vedolizumab at later time points (54 weeks and beyond) 14, 26 ; however, this is the first evaluation of predictors of early symptomatic response. In fact, multivariate regression analyses in this study indicated that baseline disease activity (MCS and CDAI scores in patients with UC and CD, respectively) was a significant predictor of symptomatic improvements at Week 2. In addition, CD duration and corticosteroid use were significant predictors of CD outcome.
Overall, our observations here are inconsistent with the current notion that anti-integrin therapies have a relatively slow onset of action. In fact, etrolizumab, an anti-integrin therapy still in development, has recently been shown to induce symptom improvement as of Week 4 in a phase 3 study in UC. 27 Our study demonstrated early symptomatic improvement with vedolizumab, achieved as of Week 2, particularly in patients naive to anti-TNF therapies, and thus has important implications on the optimal positioning of vedolizumab in treatment algorithms. However, for patients who show a modest initial improvement, continued treatment and assessment through Week 14 is recommended. 28 
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